We have surveyed the mutations of TSC1 and TSC2 from 38 (25 sporadic, 11 familial, and 2 unknown) Japanese patients with tuberous sclerosis complex. In 23 of 38 subjects, we detected 18 new mutations in addition to 4 mutations that had been previously reported. We also found 3 new polymorphisms. The mutations were not clustered on a particular exon in either of the genes. Seven TSC1 mutations found in 3 familial and 4 sporadic cases were on the exons (3 missense, 2 nonsense point mutations, a 1-base insertion, and a 2-bp deletion). Fifteen TSC2 mutations were found in 5 familial cases, 10 sporadic cases, and 1 unknown case. The 12 mutations were on the exons (8 missense, 1 nonsense point mutations, a 1-bp insertion, a 5-bp deletion, and a 4-bp replacement) and 3 point mutations were on the exon-intron junctions. Although the patients with TSC2 mutations tend to exhibit relatively severe mental retardation in comparison to those with TSC1 mutations, a genotype-phenotype correlation could not yet be established. The widespread distribution of TSC1/TSC2 mutations hinders the development of a simple diagnostic test, and the identification of individual mutations does not provide the prediction of prognosis.
Introduction
Tuberous sclerosis complex (TSC) is an autosomal dominant disease with an estimated prevalence of 1 in 10,000 in the Caucasian population and 1 in 31,000 in the Japanese population (Ohno et al. 1981; Gomez 1988) . Multiple organs are affected in TSC, including the central nervous system (mental retardation, epilepsy), skin (facial angiofibroma, shagreen patches, hypopigmented macules, periungual fibromas), heart (cardiac rhabdomyomas), and kidney (cysts, angiomyolipoma).
There are two causative genes of TSC. The TSC1 (hamartin) is located on 9q34 and consists of 23 exons. The TSC2 (tuberin) is located on 16p13.3 and consists of 41 exons (European Chromosome 16 Tuberous Sclerosis Consortium 1993; Van Slegtenhorst et al. 1997 ). Loss of heterozygosity (LOH) of either TSC1 or TSC2 in the affected tissues indicates that both act as a tumor suppressor (Green et al. 1994; Henske et al. 1995 Henske et al. , 1996 Sepp et al. 1996) . Multiple isotypes of tuberin are generated by alternative splicing at two different exons (exon 25 and 31) of TSC2 (Xiao et al. 1997) . Since the identification of the TSC1/ TSC2 genes, the mutations in Caucasian TSC patients have been extensively surveyed (Kumar et al. 1995 a,b; Vrtel et al. 1996; Wilson et al. 1996; Bajek et al. 1997; Jones et al. 1997; Maheshwar et al. 1997; Van Slegtenhorst et al. 1997; Au et al. 1997 Au et al. , 1998 . The mutations in Japanese TSC patients, however, have remained unknown.
In the present study, we surveyed the mutations in Japanese patients and assessed the relationship between the mutations and clinical symptoms.
Materials and methods

Patients and sample collection
Thirty-eight (25 sporadic, 11 familial, and 2 unknown) Japanese TSC patients were clinically diagnosed according to the criteria (Gomez 1988) . In some cases, ultrasound renogra-phy, MRI, and CT brain scan gave supportive evidence for the diagnosis. Genomic DNAs were prepared from the blood samples as described (Nanba et al. 1995) . Healthy Japanese volunteer DNA as normal controls were extracted by the Nucleic Acid Purification System (MagExtractor MFX-2000; Toyobo, Osaka, Japan) from 100µl blood.
Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis All coding exons of TSC1 and TSC2 were analyzed for every patient. Sets of PCR primers for the 41 exons of TSC2 were designed based on the TSC2 sequence, except for the primers for exon 13 and 25, which were kindly obtained by Dr. J.R. Sampson at the University of Wales, Cardiff, UK (Table 1 ). The primer information for the 21 coding exons of the TSC1 gene was obtained from Dr. O Hino in the Department of Experimental Pathology, Cancer Institute, Tokyo, Japan, and Dr. D.J. Kwiatkowski in Brigham and Womens' Hospital, Boston, USA, except for the primers for exon 9 (CACTGAGTTGACACTCTG-AAG and CTGAACTAAGTCTTACTCCAG), which were originally designed. PCR contained 25 ng of the genomic DNA as a template, 10 pmol of each primer, 0.25µM of each dNTP, 0.1 unit of Ampli Taq Gold (Perkin-Elmer, Norwalk, CT, USA), and a buffer in a total volume of 5 µl. Cycling conditions were as follows: an initial denaturation at 95°C for 10 min followed by 30 cycles of denaturation at 95°C for 1 min, annealing at 65°C for 1min and elongation at 72°C for 1 min, with a final extension at 72°C for 5 min. All the PCR products were analyzed on 1.5% agarose gel. SSCP analysis was performed as described (Orita et al. 1989; Yuasa et al. 1997) . Using a minigel (10 ϫ 10 cm), the samples were analyzed under four different electrophoresis conditions, in a combination of two sets of gel mixtures (12% polyacrylamide gel with or without 5% glycerol) and two temperature conditions (4°C or 22°C). 
Results
SSCP analysis
A total of 25 variants were detected by SSCP analysis (Fig.  1 ) from 23 patients (60% of the total 38 patients). Seven variants of TSC1 gene were detected in 3 familial cases and 4 sporadic ones. Fifteen variants of TSC2 gene were detected in 5 familial cases, 10 sporadic cases, and one unknown case. L574L of TSC1 and I531I of TSC2 genes were considered to be polymorphisms because the point mutations did not cause amino acid substitution. M322T of TSC1 was detected in the normal controls (6 of 80) and was supposed to represent a polymorphism (Table 2A ). All other missense mutations were not detected in 60 or 100 normal controls. Any DNA sample from the parents was not available except for P28.
Mutations in TSC1 gene
Two nonsense, two frame shift, and three missense mutations were located in various exons of the gene. Two mutations (R509X, Q654E) in three patients were located in exon 15, and the R509X was found both in a sporadic patient (P26) and a familial patient (P3). Two mutations (W676X and T417I) were found in one patient (P31).
Mutations in TSC2 gene
One nonsense, 3 frame shift, and 8 missense mutations were identified in 16 patients (Table 2B ). The two single nucleotide substitutions (2760 ϩ 1 G to A, 5179 Ϫ 1 G to T) of an exon-intron junction were predicted to cause a splicing error. Although a substitution (5178 ϩ 5 G to A) in the intron was not in the consensus sequence of the splicing, the mutation was located 5 bp distant from the exon and was not detected in 100 normal controls. The mutation might cause a splicing error. L717R in a patient with pulmonary tuberous sclerosis was reported previously (Zhan et al. 1999) . Both the V769E mutation (P2 and P21) and R1459X mutation (P6 and P8) were detected in 2 unrelated sporadic patients. Two missense mutations (H137R and D647N) Fig. 1 . PCR-SSCP analysis of the TSC1/TSC2 genes. Arrows indicate the aberrant bands found in the patients' samples. C, control samples from healthy subjects; P, patients' samples were found in the same patient (P32). P1657L in P28 was confirmed to be a de novo mutation by examination of the parents' samples.
Clinical symptoms and mutation types
The clinical symptoms and the gene mutations are summarized in Table 3 . The number of the patients with mental retardation (ϩ and ϩϩ) in TSC2 was significantly larger than that in TSC1 ( 2 ϭ 4.8, P ϭ 0.0285). The severity of mental retardation of the patients with TSC1 mutations appeared to be milder than that of the patients with TSC2 mutations. Complete information on renal and cardiac involvements was not available and could not be assessed. None of the mutation types (missense, nonsense, frame shift, and splicing) appeared to be correlated with a specific clinical symptom. In particular, the R509X mutation in TSC1 was detected in two patients, and the severity of mental retardation in these patients were quite different.
Discussion
Mutations in a given gene may be screened by various methods such as Southern blot analysis, SSCP, heteroduplex analysis, protein truncation test, and RT-PCR followed by SSCP (Kumar et al. 1995a,b; Vrtel et al. 1996; Wilson et al. 1996; Bajek et al. 1997; Jones et al. 1997; Maheshwar et al. 1997; Au et al. 1997 Au et al. , 1998 . In the present study, we employed SSCP to survey the mutations of TSC1 and TSC2 genes because the method is simple enough to cover the multiple numbers of exons. To increase the mutation detection rate of SSCP, we used four electrophoresis conditions by a combination of different sets of temperature and glycerol content of the gel. Our mutation detection rate was 60% (23 of 38), which is comparable with those in other reports Van Slegtenhorst et al. 1997; Au et al. 1998) .
There are several possible explanations for the failure to detect of TSC1/TSC2 mutations in the 15 patients. First, it can be false negative. One report showed that the SSCP The original amino acid and its position in the protein (numbered from the initiator Met as 1) are followed by a new amino acid for missense mutations, and by X for nonsense mutation a,b The identical change was reported by Van Slegtenhorst et al. (1997) c The identical change was reported by Wilson et al. (1996) d The identical change was reported by Maheshwar et al. (1997) method to detect a point mutation on a 250-bp DNA fragment was 63% effective (Sheffield et al. 1993) . Second, it may be true negative in those cases in which the mutation lies outside of the coding sequence, either in the 5Ј-regulatory elements, within the intronic sequences, or in the 3Ј-UTR. In addition, a large-scale rearrangement of genomic DNA may yield true negative results in the SSCP of the coding exons. Although there is no report of a large-scale mutation in TSC1, there are indeed some in TSC2 The European Chromosome 16 Tuberous Sclerosis Consortium 1993; Au et al. 1997; Van Slegtenhorst et al. 1997) . The mutation surveys of TSC1/TSC2 genes in Caucasian TSC patients revealed no clustering of the mutation in either gene (Wilson et al. 1996; Jones et al. 1997; Van Slegtenhorst et al. 1997; Au et al. 1998) . In accordance with these previous findings, the 22 mutations (18 new and 4 reported) found in this study were distributed on various exons and there was no clustering of the mutations. Again in accordance with the previous findings, there was no obvious relationship between the type and location of the mutation and the clinical symptoms. However, the patients with TSC2 mutations appeared to have more severe mental retardation compared with the patients with TSC1 mutations. The same tendency has been noted . It is therefore at least clear that the clinical phenotype cannot be predicted from the genotype. Because of the heterogeneity of the mutations, it also appears impossible at present to develop a simple diagnostic test for TSC. 
